May 28, 2021

The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immune response, immunity

• [Pre-print, not peer-reviewed] Anti-SARS-CoV-2 spike antibodies were detected in 80% of chronic hemodialysis patients (n=66) 28 days after a single dose of the Pfizer-BioNTech vaccine in a cohort study in Toronto, Canada. However, only 23% mounted a robust response defined by exceeding the median level of anti-spike antibodies observed in serum of healthy convalescent controls (n=35). Anti-spike antibodies were detected in 96% of patients receiving two doses (n=76), but only 72% mounted a robust response. Similar patterns were observed for detectable anti-receptor binding domain (RBD) antibodies.

Yau et al. (May 27, 2021). The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients. Pre-print downloaded May 28 from https://doi.org/10.1101/2021.05.24.21257425